Advertisement
ICLR vs VIVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICLR is a Buy and VIVO is a Buy.
ICLR's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ICLR turned positive on October 15, 2026. Looking at past instances where ICLR's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ICLR as a result. In 64 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
ICLR moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICLR crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +17.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in 202 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 137 of 220 cases where ICLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for ICLR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
ICLR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ICLR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.676) is normal, around the industry mean (65.986). ICLR's P/E Ratio (304.134) is considerably higher than the industry average of (3.066). Projected Growth (PEG Ratio) (0.533) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.626) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
VIVO's Stochastic Oscillator descends into oversold zone
The Stochastic Oscillator for VIVO moved into oversold territory on November 03, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for VIVO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +15.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVO advanced for three days, in 186 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
VIVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIVO as a result. In 79 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for VIVO turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for VIVO moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVO entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.139) is normal, around the industry mean (16.526). P/E Ratio (-0.833) is within average values for comparable stocks, (57.809). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.287) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (103.889).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
ICLR | VIVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 90 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 85 | |
P/E GROWTH RATING 1..100 | 1 | 8 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ICLR's Valuation (93) in the Pharmaceuticals Other industry is in the same range as VIVO (95) in the Biotechnology industry. This means that ICLR’s stock grew similarly to VIVO’s over the last 12 months.
ICLR's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as VIVO (100) in the Biotechnology industry. This means that ICLR’s stock grew similarly to VIVO’s over the last 12 months.
ICLR's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as VIVO (100) in the Biotechnology industry. This means that ICLR’s stock grew similarly to VIVO’s over the last 12 months.
ICLR's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for VIVO (85) in the Biotechnology industry. This means that ICLR’s stock grew somewhat faster than VIVO’s over the last 12 months.
ICLR's P/E Growth Rating (1) in the Pharmaceuticals Other industry is in the same range as VIVO (8) in the Biotechnology industry. This means that ICLR’s stock grew similarly to VIVO’s over the last 12 months.
| ICLR | VIVO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 72% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 67% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 90% |
| Advances ODDS (%) | 7 days ago 66% | 8 days ago 84% |
| Declines ODDS (%) | 2 days ago 69% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ICLR’s FA Score shows that 1 FA rating(s) are green while VIVO’s FA Score has 1 green FA rating(s).
- ICLR’s FA Score: 1 green, 4 red.
- VIVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ICLR’s TA Score shows that 6 TA indicator(s) are bullish while VIVO’s TA Score has 4 bullish TA indicator(s).
- ICLR’s TA Score: 6 bullish, 4 bearish.
- VIVO’s TA Score: 4 bullish, 5 bearish.
Price Growth
ICLR (@Medical Specialties) experienced а +11.36% price change this week, while VIVO (@Computer Communications) price change was -39.16% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.30%. For the same industry, the average monthly price growth was -5.24%, and the average quarterly price growth was +42.12%.
The average weekly price growth across all stocks in the @Computer Communications industry was -6.19%. For the same industry, the average monthly price growth was -11.87%, and the average quarterly price growth was -6.36%.
Reported Earning Dates
ICLR is expected to report earnings on Feb 24, 2027.
VIVO is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Medical Specialties (-2.30% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Computer Communications (-6.19% weekly)Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.
Advertisement
VIVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIVO has been loosely correlated with INSP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVO jumps, then INSP could also see price increases.
| Ticker / NAME | Correlation To VIVO | 1D Price Change % | ||
|---|---|---|---|---|
| VIVO | 100% | -27.44% | ||
| INSP - VIVO | 41% Loosely correlated | -7.90% | ||
| ICLR - VIVO | 38% Loosely correlated | -0.67% | ||
| BRKR - VIVO | 37% Loosely correlated | +1.45% | ||
| GMED - VIVO | 36% Loosely correlated | +0.15% | ||
| TMO - VIVO | 35% Loosely correlated | +2.30% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CDEI | 93.77 | N/A | N/A |
| Calvert US Large-Cap Diversity, Equity and Inclusion Index ETF (CDEI) | |||
| PWRL | 11.32 | N/A | N/A |
| Powerlaw Corp | |||
| DDX | 24.96 | -0.01 | -0.03% |
| Defined Duration 10 ETF (DDX) | |||
| DFIP | 39.85 | -0.07 | -0.18% |
| Dimensional Inflation-Protected Securities ETF (DFIP) | |||
| KSTR | 16.72 | -0.43 | -2.51% |
| KraneShares China Technology & Semiconductor STAR 50 Index ETF (KSTR) | |||